
DID YOU KNOW?

Colon cancer can affect people of all genders and race



Time to get screened![1]
COLON CANCER IS ON THE RISE IN YOUNGER PEOPLE[2]

45[1]

MANY PEOPLE HAVE NO SYMPTOMS
in the early stages of colon cancer[3]

WHEN CAUGHT EARLY, COLON CANCER IS TREATABLE IN 9 OUT OF 10 PEOPLE[4]**

9 OUT OF 10

SCREENING OPTIONS

	Colonoscopy	Cologuard® Test	FIT	Blood-based Test
How it works	• Uses a scope to look for and remove abnormal growths in the colon/rectum[5]	• Uses stool DNA to detect abnormal cells and blood[5]	• Tests for blood hidden in stool[5]	• Tests for DNA changes from a blood sample[6]
Where do I do it?	• Hospital/outpatient clinic	• Use at home. Send to lab for results	• Use at home. Send to lab for results	• Clinic, lab or mobile phlebotomy
How often should I do it?‡	10 Screen again in 10 years[5]	3 Screen again in 3 years[5]	1 Screen again every year[5]	3 Screen again in 3 years[6]
Approved to detect precancers?[7]	Yes[8]	Yes FDA-indicated[9]	Not FDA-indicated[10]	Not FDA-indicated[6*]
Other factors	• If results are abnormal, polyps removed and examined • Anesthesia required • Covered by most insurance[11†]	• If results are abnormal, colonoscopy needed • No diet restrictions • Covered by most insurance[11†]	• If results are abnormal, colonoscopy needed • May require diet restrictions • Covered by most insurance[11†]	• If results are abnormal, colonoscopy needed • Only covered by Medicare Part B[12]

TALK TO YOUR DOCTOR about which one might be right for you.

COLOGUARD.COM

*Current FDA-approved CRC blood test not indicated for precancer detection.
**Based on 5-year survival rates.
†Insurance coverage can vary; only your insurer can confirm how colon cancer screening is covered under your insurance policy.
‡Adhering to the recommended frequency is a crucial step. Screening may be recommended more frequently depending on the findings of a screening colonoscopy.


REFERENCES: 1. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guidelines update from the *American Cancer Society*. *CA Cancer J Clin*. 2018; 68(4): 250-281. doi:10.3322/caac.21457. **2.** Siegel RL, Wagle NS, Jemal A. Leading Cancer Deaths in People Younger Than 50 Years. *JAMA*. Published online January 22, 2026. doi:10.1001/jama.2025.25467. **3.** CDC. Symptoms of colorectal cancer. Updated June 12, 2024. Accessed February 23, 2026. https://www.cdc.gov/colorectal-cancer/symptoms/index.html **4.** ACS. Cancer facts & figures 2026. Atlanta: *American Cancer Society*; 2026. **5.** Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: Us Preventative Services Task Force recommendation statement. *JAMA*. 2021;325(19):1965-1977. **6.** Shield Provider Brochure. Guardant Health. Accessed December 3, 2024. https://shieldcancerscreen.com/wp-content/uploads/LBL-000351-R1-Shield-Provider-Labeling.pdf **7.** Screening tests to detect colorectal cancer and polyps. National Cancer Institute. Reviewed October 29, 2024. Accessed May 22, 2025. https://www.cancer.gov/types/colorectal/screening-fact-sheet **8.** Colorectal cancer early detection, diagnosis, and staging. American Cancer Society. Accessed May 22, 2025. https://www.cancer.org/content/dam/CRC/PDF/Public/8606.00.pdf **9.** Exact Sciences. 2026. Cologuard and Cologuard Plus Clinician Brochure. **10.** FDA 510(k) substantial equivalence determination decision summary: K092330. US Food and Drug Administration. Accessed May 22, 2024.https://www.accessdata.fda.gov/cdrh_docs/reviews/K092330.pdf **11.** ACS. Colorectal Cancer Early Detection, Diagnosis, and Staging. Updated January 29, 2024. Accessed February 16, 2026. https://www.cancer.org/content/dam/CRC/PDF/Public/8606.00.pdf **12.** Guardant Health. Guardant Health's FDA-approved sheild blood test now commercially available in U.S. as a primary screening option for colorectal cancer. Accessed February 16, 2026 investors.guardanthealth.com/press-releases/2024/ Guardant-Healths-FDAap-proved-Shield-Blood-Test-Now-Commercially- Available-in-U.S-as-a-Primary-Screening-Option-for-Colorectal-Cancer/default.aspxtt

Cologuard and Exact Sciences are registered trademarks of Exact Sciences Corporation. ©2026 Exact Sciences Corporation. All rights reserved. M-US-CG-06585

EXACT SCIENCES®

¿SABÍA QUE...?

El cáncer de colon puede afectar a personas de todos los géneros y razas



¡Es hora de hacerse una prueba de detección![1]

EL CÁNCER DE COLON ESTÁ EN AUMENTO EN PERSONAS MÁS JÓVENES[2]

45[1]



MUCHAS PERSONAS NO TIENEN SÍNTOMAS en las primeras etapas del cáncer de colon[3]

CUANDO SE DETECTA TEMPRANO, EL CÁNCER DE COLON ES TRATABLE EN 9 DE CADA 10 PERSONAS[4]***

9 DE CADA 10

OPCIONES DE DETECCIÓN

	Colonoscopia	Prueba Cologuard®	Prueba inmunoquímica fecal	Prueba basada en sangre
Cómo funciona	• Se utiliza un endoscopio para buscar y extirpar crecimientos anormales en el colon/recto[5]	• Se utiliza el ADN contenido en las heces para detectar células anómalas y sangre oculta[5]	• Detecta sangre oculta en las heces[5]	• Detecta cambios en el ADN a partir de una muestra de sangre[6]
¿Dónde la hago?	• Hospital/clínica ambulatoria	• Úsela en el hogar. Envíela al laboratorio para obtener los resultados	• Úsela en el hogar. Envíela al laboratorio para obtener	• Clínica, laboratorio o unidad de flebotomía móvil
¿Con qué frecuencia debo hacerla?‡	Repetir la prueba en 10 años[5]	Repetir la prueba en 3 años[5]	Repetir la prueba cada año[5]	Repetir la prueba en 3 años[6]
¿Aprobada para detectar precánceres?[7]	Sí[8]	Sí indicada por la FDA[9]	No indicada por la FDA[10]	No indicada por la FDA[6*]
Otros factores	• Si los resultados son anormales, se retiran los pólipos y se examinan • Se requiere anestesia • Cubierta por la mayoría de los seguros médicos[11†]	• Si los resultados son anormales, se requiere colonoscopia • Sin restricciones de alimentos • Cubierta por la mayoría de los seguros médicos[11†]	• Si los resultados son anormales, se requiere colonoscopia • Puede requerir restricciones de alimentos • Cubierta por la mayoría de los seguros médicos[11†]	• Si los resultados son anormales, se requiere colonoscopia • Solo cubierta por Medicare Parte B[12]

CONSULTE A SU MÉDICO sobre cuál podría ser la adecuada para usted.

COLOGUARD.COM

*Prueba de detección del CCR en sangre actualmente aprobada por la FDA, no indicada para la detección de precáncer.
**Con base en las tasas de supervivencia a 5 años.
†La cobertura del seguro puede variar; solo su aseguradora puede confirmar cómo su póliza de seguro cubre la prueba de detección del cáncer de colon.
‡El cumplimiento de la frecuencia recomendada es un paso crucial. La detección puede recomendarse con mayor frecuencia dependiendo de lo que se encuentre en una colonoscopia de detección.

REFERENCIAS: 1. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guidelines update from the *American Cancer Society*. *CA Cancer J Clin*. 2018; 68(4): 250-281. doi:10.3322/caac.21457. **2.** Siegel RL, Wagle NS, Jemal A. Leading Cancer Deaths in People Younger Than 50 Years. *JAMA*. Published online January 22, 2026. doi:10.1001/jama.2025.25467. **3.** CDC. Symptoms of colorectal cancer. Updated June 12, 2024. Accessed February 23, 2026. https://www.cdc.gov/colorectal-cancer/symptoms/index.html **4.** ACS. Cancer facts & figures 2026. Atlanta: *American Cancer Society*; 2026. **5.** Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: Us Preventative Services Task Force recommendation statement. *JAMA*. 2021;325(19):1965-1977. **6.** Shield Provider Brochure. Guardant Health. Accessed December 3, 2024. https://shieldcancerscreen.com/wp-content/uploads/LBL-000351-R1-Shield-Provider-Labeling.pdf **7.** Screening tests to detect colorectal cancer and polyps. National Cancer Institute. Reviewed October 29, 2024. Accessed May 22, 2025. https://www.cancer.gov/types/colorectal/screening-fact-sheet **8.** Colorectal cancer early detection, diagnosis, and staging. American Cancer Society. Accessed May 22, 2025. https://www.cancer.org/content/dam/CRC/PDF/Public/8606.00.pdf **9.** Exact Sciences. 2026. Cologuard and Cologuard Plus Clinician Brochure. **10.** FDA 510(k) substantial equivalence determination decision summary: K092330. US Food and Drug Administration. Accessed May 22, 2024.https://www.accessdata.fda.gov/cdrh_docs/reviews/K092330.pdf **11.** ACS. Colorectal Cancer Early Detection, Diagnosis, and Staging. Updated January 29, 2024. Accessed February 16, 2026. https://www.cancer.org/content/dam/CRC/PDF/Public/8606.00.pdf **12.** Guardant Health. Guardant Health's FDA-approved sheild blood test now commercially available in U.S. as a primary screening option for colorectal cancer. Accessed February 16, 2026 investors.guardanthealth.com/press-releases/2024/ Guardant-Healths-FDAapproved-Shield-Blood-Test-Now-Commercially- Available-in-U.S-as-a-Primary-Screening-Option-for-Colorectal-Cancer/default.aspxtt

Cologuard y Exact Sciences son marcas comerciales registradas de Exact Sciences Corporation. ©2026 Exact Sciences Corporation. Todos los derechos reservados. M-US-CG-05113

EXACT SCIENCES.